{
    "clinical_study": {
        "@rank": "48586", 
        "arm_group": {
            "arm_group_label": "ASP0113 group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in\n      subjects undergoing allogeneic HCT.  The occurrence of CMV viremia and immunogenicity are\n      also assessed."
        }, 
        "brief_title": "A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allogeneic Hematopoietic Cell Transplant", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is planned to undergo either of the following:\n\n               -  Sibling Donor Transplant - 7/8 Human Leukocyte Antigen (HLA)-A, -B, -C, -DR\u00df1\n                  match utilizing high resolution typing or 8/8 (HLA)-A, -B, -C, -DR\u00df1 match\n                  utilizing low or high resolution typing.\n\n               -  Unrelated Donor Transplant - 7/8 or 8/8 HLA-A, -B, -C, -DR\u00df1 match utilizing\n                  high resolution typing.\n\n          -  Subject has one of the following underlying diseases: Acute myeloid leukemia (AML)\n             /Acute lymphoblastic leukemia (ALL) / Acute undifferentiated leukemia (AUL) /Acute\n             biphenotypic leukemia / Chronic myelogenous leukemia (CML) / Chronic lymphocytic\n             leukemia (CLL) / myelodysplastic syndrome(s) (MDS)\n\n          -  Subject is scheduled to receive an allogeneic peripheral blood stem cell (PBSC) or\n             bone marrow transplant (BMT) for the treatment of hematologic disorders\n\n        Exclusion Criteria:\n\n          -  Subject has active CMV disease or infection or has received treatment for active CMV\n             disease or infection within 90 days prior to transplant\n\n          -  Subject has planned CMV prophylactic therapy with antiviral drugs or CMV-specific\n             immunoglobulins\n\n          -  Subject has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score\n             > 3\n\n          -  Subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B\n             surface antigen or hepatitis C ribonucleic acid (RNA)\n\n          -  Subject has received any of the following substances or treatments:\n\n               -  T-cell depletion of donor cell product.\n\n               -  Tlemtuzumab within 60 days prior to transplant, including conditioning regimen.\n                  Subjects for whom treatment with alemtuzumab is planned at any time from 60 days\n                  prior to through one year post-transplant should not be enrolled in the trial.\n\n               -  Administration of a CMV vaccine, including any prior exposure to ASP0113.\n\n          -  Subject has received an allogeneic stem cell transplant within one year prior to\n             transplant\n\n          -  Subject has a current malignancy in addition to the malignancy being treated for the\n             study or the subject has a history of any other malignancy\n\n          -  Subject has an unstable medical or psychiatric condition, including a history of\n             illicit drug(s) or alcohol abuse that the Investigator believes will interfere with\n             protocol requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903928", 
            "org_study_id": "0113-CL-1003"
        }, 
        "intervention": {
            "arm_group_label": "ASP0113 group", 
            "description": "injection", 
            "intervention_name": "ASP0113", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "cytomegalovirus", 
            "DNA vaccine", 
            "transplantation", 
            "HCT"
        ], 
        "lastchanged_date": "July 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, vital signs, physical exam and labo-tests", 
            "safety_issue": "No", 
            "time_frame": "for 365 days after HCT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "protocol-specified reactogenicity scale", 
                "measure": "Local reactogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "for 14 days following each injection"
            }, 
            {
                "description": "CMV plasma viral load \u2265 1000 copies", 
                "measure": "Incidence of CMV viremia", 
                "safety_issue": "No", 
                "time_frame": "for 365 days after HCT"
            }, 
            {
                "description": "CMV-specific AVT(Anti-virus therapy)  initiated for a CMV plasma viral load \u2265 1000 copies", 
                "measure": "CMV-specified antiviral therapy", 
                "safety_issue": "No", 
                "time_frame": "for 365 days after HCT"
            }, 
            {
                "description": "CMV pneumonia, CMV gastroenteritis, CMV hepatitis, et al", 
                "measure": "Incidence of cytomegalovirus end-organ disease (CMV EOD)", 
                "safety_issue": "No", 
                "time_frame": "for 365 days after HCT"
            }, 
            {
                "measure": "Maximum grade of Graft Versus Host Disease (GVHD)", 
                "safety_issue": "No", 
                "time_frame": "for 365 days after HCT"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}